Extracorporeal immunoadsorption treatment for rheumatoid arthritis
Hailey D, Topfer L A

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
To summarise the available evidence on extracorporeal immunoadsorption treatment for rheumatoid arthritis.

Authors' conclusions
- Immunoadsorption treatment is a non-drug therapy for rheumatoid arthritis. The treatment is based on filtering the patient's plasma through a column containing staphylococcal protein A.

- The treatment is effective in alleviating the symptoms of severe rheumatoid arthritis in some patients. Data on long-term outcomes are not available.

- The mechanism of action of this treatment is unclear.

- Most adverse effects are associated with the apheresis procedure.

- The cost per 12 week course of treatment is likely to be more than 20,000 Canadian dollars. The cost-effectiveness of the technology is not yet established.

Project page URL
https://www.ccohta.ca/research/index.html

Indexing Status
Subject indexing assigned by CRD

MeSH
Arthritis, Rheumatoid /therapy; Costs and Cost Analysis

Language Published
English, French

Country of organisation
Canada

Address for correspondence
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392; Email: jills@ccohta.ca.

AccessionNumber
32002000367